Exploratory anchor-based analyses to determine minimal clinically important differences for the Brief Assessment of Cognition in Schizophrenia and the Schizophrenia Cognition Rating Scale.

Hans S Klein¹, Reuben H Fan², Tingting Ge², Mahnaz Asgharnejad³, Chris Brady⁴, Elizabeth Hanson³, Philip D Harvey⁵, Jan Sedway⁴, Venkatesha Murthy³, Richard S E Keefe⁶, Jaskaran B Singh², Ni A Khin²

¹Neurocrine Biosciences, Inc., San Diego, CA, USA. Electronic address: hklein@neurocrine.com.

²Neurocrine Biosciences, Inc., San Diego, CA, USA.

³Takeda Development Center Americas, Inc., Cambridge, MA, USA.

⁴Clario, Philadelphia, PA, USA.

⁵Department of Psychiatry, University of Miami Miller School of Medicine, Miami, FL, USA.

⁶Duke University, Durham, NC, USA.

PubMed DOI

Abstract

BACKGROUND: The Brief Assessment of Cognition in Schizophrenia (BACS) and Schizophrenia Cognition Rating Scale (SCoRS) tests help to assess cognition in schizophrenia; however, anchor-based determinations of meaningful change are needed. This analysis derived minimal clinically important difference (MCID) estimates using data from INTERACT, a phase 2 randomized study of luvadaxistat as treatment o…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.